Labiotech.eu

News and Trends 11 Mar 2016

Reviewing Immuno-Oncology: What works and what doesn’t

Researchers from Leiden University Medical Center (LUMC) and ISA Pharmaceuticals (Netherlands) have authored an extensive review of what is working in immuno-oncology – and what hasn’t. The review was accepted in the well-known journal Nature Reviews Cancer and it covers the findings of 250 peer-reviewed papers about immunotherapies. Immuno-oncology is radically changing the way cancer is being […]

March 11, 2016 - 4 minutesmins - By Denise Neves Gameiro

News and Trends 11 Mar 2016

Interview: Can this Natural Acid replace Petroleum for the Chemical and Biofuel Industries?

GFBiochemicals in (Italy) is producing levulinic acid (from breakdown of biomass) to replace petroleum-based products for a huge range of sectors, with up to a $30Bn market volume. We had the chance to meet Marcel Van Berkel, the CMO of GFBiochemicals, which is based in Milan with additional Netherlands and Minnesota (US) sites. Berkel told us more about the many […]

March 11, 2016 - 4 minutesmins - By Marie Godar

News and Trends 11 Mar 2016

Biotech of the Week: Mission Therapeutics and a Cambridge Pathway against Cancer

From East to West, this week we say goodbye to Hungary and head up towards Queen Elizabeth II’s United Kingdom. Cambridge, known for its World renowned Academia is where Mission Therapeutics, our Biotech of the Week is located. City: Cambridge (UK) Founded: 2011 Employees: 30 Total raised: €110M (as of 02/2016) CEO: Anker Lundemose Mission: Founded in 2011, Mission Therapeutics, […]

March 11, 2016 - 1 minutemin - By Joachim Eeckhout

News and Trends 10 Mar 2016

Antibody Start-up Gets a Slice of a Rebranded €210M Life Sciences Fund

Capella Biosciences (UK) is a life sciences start-up specializing in antibodies. It has just raised an additional €14.3M in a Series A round to develop their antibody pipeline to clinical stages. Capella started out in 2014 and based in London, defining its mission as developing therapeutic monoclonal antibodies for unmet medical needs. Back then, it received […]

March 10, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 10 Mar 2016

The Largest Scandinavian Biotech Fundraising of 2016 has just been Signed

Aprea (Sweden) is not a well-know Biotech (yet), but has succeeded in raising €46M from big investors in the US and Europe. Why? For its First-in-class potential for a famous cancer target… Aprea started in 2003 as a spin-off from cancer research at Karolinska Institutet, in its technology-transfer program. This Biotech has a promising candidate […]

March 10, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 10 Mar 2016

How this Forensic DNA Tool can help Conserve Endangered Species in the UK

This is the story of how the Natural History Museum of Denmark and Molecular Ecology biotech Spygen (France) brought together forensic science techniques to detect traces of Great Crested Newt DNA in UK ponds. The Great Crested Newt (Triturus cristatus) is an amphibian found across Northern Europe and parts of Asia, which has been declining since […]

March 10, 2016 - 3 minutesmins - By Joachim Eeckhout

News and Trends 9 Mar 2016

EMA Launches its own Fast Track for Breakthrough Therapies

The European Medicine Agency (EMA) is launching a priority scheme for therapies addressing unmet medical needs, similar to the FDA’s fast track. The key objective is to help European patients get earlier access to therapies that could be lifesaving, and this could have significant impact on the European Biotech industry. This new PRIME fast-track will include a […]

March 9, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 9 Mar 2016

Significant doubts about Welsh Government handling of Biotech VC fund

The Wales Life Sciences Fund was intended to attract Biotechs and Pharma to this part of the UK – but the governmental oversight of the establishment of this £50M fund has been criticised in a report by the Wales Audit Office… [Editor’s note: this article was initially published on March 7th, 2016. Due to some inaccuracies, we […]

March 9, 2016 - 3 minutesmins - By Joachim Eeckhout

News and Trends 9 Mar 2016

Boehringer Ingelheim Gets €540M upfront for the next Potential Antibody Blockbuster

Boehringer Ingelheim (Germany) has entered a new collaboration with AbbVie (US) to develop two new candidates for immune diseases, including psoriasis and Crohn’s disease. Therapies for immune diseases continue to attract Pharma’s attention (and money). This time, two of 25 leading Big Pharma worldwide, AbbVie and Boehringer Ingelheim, have partnered to develop 2 different immunological candidates. […]

March 9, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 8 Mar 2016

Irish Gene Therapy for Blindness is Acquired by US Leader in the Field

Spark Therapeutics (US) has paid over €13.5M for Genable Technologies (Ireland) and its gene therapy for a degenerative eye disease which progresses to blindness. Spark Therapeutics is one of the players in the re-emerging field of Gene Therapy (which is already establishing records like the most expensive drug). It focuses on debilitating genetic diseases, like inherited […]

March 8, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 8 Mar 2016

Sanofi Genzyme goes to Phase III with Rare Neuromuscular Disease

Sanofi Genzyme (Boston and France) have obtained good phase I/II results with a candidate for the rare Pompe Disease and expects to move to phase III in the second quarter of 2016. Sanofi Genzyme continues to bet on rare diseases and neurodegenerative disorders, now with a therapy for late-onset Pompe Disease. Pompe Disease is a […]

March 8, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 7 Mar 2016

Swedish Investment loses €8M over failed Phase I/II for Leukemia

Akinion (Sweden) will stop the development of its candidate for leukemia, after patients in phase I/II have experienced liver toxicity. As a result, main investor Karolinska Development takes an €8M hit in its portfolio valuation. Sad news for Akinion. This Stockholm-based drug developer decided to halt the development of its lead candidate, APN-028. This happens after […]

March 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Reviewing Immuno-Oncology: What works and what doesn’t

Interview: Can this Natural Acid replace Petroleum for the Chemical and Biofuel Industries?

Biotech of the Week: Mission Therapeutics and a Cambridge Pathway against Cancer

Antibody Start-up Gets a Slice of a Rebranded €210M Life Sciences Fund

The Largest Scandinavian Biotech Fundraising of 2016 has just been Signed

How this Forensic DNA Tool can help Conserve Endangered Species in the UK

EMA Launches its own Fast Track for Breakthrough Therapies

Significant doubts about Welsh Government handling of Biotech VC fund

Boehringer Ingelheim Gets €540M upfront for the next Potential Antibody Blockbuster

Irish Gene Therapy for Blindness is Acquired by US Leader in the Field

Sanofi Genzyme goes to Phase III with Rare Neuromuscular Disease

Swedish Investment loses €8M over failed Phase I/II for Leukemia

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!